Abide Therapeutics

San Diego, United States Founded: 2011 • Age: 15 yrs Acquired By Lundbeck
Serine hydrolase inhibitors are developed for pain management.

About Abide Therapeutics

Abide Therapeutics is a Healthcare company based in San Diego (United States) founded in 2011, and was acquired by Lundbeck in May 2019. Serine hydrolase inhibitors are developed for pain management. Abide Therapeutics has raised $12.2 million across 2 funding rounds from investors including Lundbeck and Cardinal Partners. The company has 47 employees. Its focus areas include Life Sciences, Pain Management, Drugs and Diversified. Its competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

Abide Therapeutics investigates serine hydrolase inhibitors for pain management. It uses a proprietary drug development platform to generate lead molecules for inhibition of serine hydrolase activity. Its lead candidate targets monoacylglycerol lipase, a type of serine hydrolase, in the endocannabinoid system. It mimics the analgesic effects of marijuana without affecting cognition and is currently in phase I clinical trials.

  • Headquarters San Diego, United States
  • Employees 47
  • Stage Acquired
  • Sectors
    Healthcare
  • Website abidetx.com
  • Social LinkedIn X
  • Acquired by Lundbeck (May 2019)
Key Metrics
  • Total Equity Funding
    $12.2M (USD)

    in 2 rounds

  • Latest Funding Round
    $10M (USD), Series B

    Feb 2014

  • Investors
    Lundbeck

    & 1 more

  • Employee Count
    47
  • Acquired by
    Lundbeck

    (May 2019)

Funding Insights of Abide Therapeutics

Abide Therapeutics has successfully raised a total of $12.2M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $12.2M
  • Total Rounds 2
  • Last Round Series B β€” $10M
  • First Round $2.2M

    (Nov 2011)

  • Investors Count 1

All 2 funding rounds of Abide Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2014$10MSeries B––
Nov 2011$2.2MSeed––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Abide Therapeutics

Abide Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Lundbeck and Cardinal Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Life science & tech focused VC firm investing in early stage companies in the US
cardinalpartners.comPrinceton, United States
Drugs for CNS disorders are developed and advanced.
1915lundbeck.comCopenhagen, Denmark
Premium access

Investor details for Abide Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Abide Therapeutics

4 dated milestones of Abide Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Abide Therapeutics is founded.
  2. Funding First funding round of $2.2M.
  3. Funding Latest funding round, Series B, of $10.0M.
  4. Exit Acquired by Lundbeck.

Competitors of Abide Therapeutics

Abide Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
flexiontherapeutics.com2007Woburn, United States$62M692
Developer of therapies for the treatment of musculoskeletal disorders
caratherapeutics.com2004New York, United States$51M79
Developer of therapeutics for pain relief and inflammatory diseases
eliemtx.com2018Boston, United States$171.3M30
Develops antibody-based treatments for autoimmune and inflammatory disorders.
Premium access

Detailed competitors of Abide Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Abide Therapeutics

The website of Abide Therapeutics (abidetx.com) receives about 3.1K visits a month.

  • Monthly visits
    3.1K

    ▲ 932.6% vs previous month

Top companies in Pain Management

3 companies that operate in the same segment as Abide Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of therapies for the treatment of musculoskeletal disorders
2007Woburn, Massachusetts, United StatesUSD 62 MUSD 85.55 M692
Developer of therapeutics for pain relief and inflammatory diseases
2004New York, New York, United StatesUSD 51 MUSD 4.33 M79
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed.
2007Philadelphia, Pennsylvania, United StatesUSD 203 MUSD 3.13 M35
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Abide Therapeutics

Premium access

Complete news archive for Abide Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abide Therapeutics

Abide Therapeutics was founded in 2011.

Abide Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Abide Therapeutics is a funded company, having raised a total of $12.2M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.2M, raised on Nov 2011.

Abide Therapeutics has 47 employees.

Abide Therapeutics investigates serine hydrolase inhibitors for pain management. It uses a proprietary drug development platform to generate lead molecules for inhibition of serine hydrolase activity. Its lead candidate targets monoacylglycerol lipase, a type of serine hydrolase, in the endocannabinoid system. It mimics the analgesic effects of marijuana without affecting cognition and is currently in phase I clinical trials.

Abide Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.

Abide Therapeutics has 2 investors. Key investors include Lundbeck, and Cardinal Partners.

Yes. Abide Therapeutics was acquired by Lundbeck in May 2019.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available